Eli Lilly and Company (LLY) has published comprehensive results from the Phase 3 SUMMIT trial, revealing that tirzepatide significantly reduced the risk of exacerbating heart failure incidents in adults afflicted with heart failure with preserved ejection fraction (HFpEF) and obesity. Furthermore, recipients of tirzepatide experienced notable enhancements in heart failure symptoms and a reduction in physical limitations.The company confirmed the achievement of primary endpoints, with tirzepatide achieving a 38% decrease in risk for heart failure outcomes, measured as a composite endpoint, compared to the placebo. The risk of heart failure-related hospitalization was reduced by 56%. Additionally, tirzepatide participants reported an almost 25-point enhancement in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), a tool used to evaluate heart failure symptoms and physical constraints, in comparison to a 15-point improvement for those on placebo.Eli Lilly reported success in all key secondary endpoints as well, with tirzepatide-treated patients exhibiting better exercise capacity, walking approximately 30 meters farther in six minutes compared to the placebo group. Patients receiving tirzepatide also experienced an average body weight reduction of 15.7%, as opposed to the placebo group’s 2.2%. Furthermore, tirzepatide significantly lowered high-sensitivity C-reactive protein (hsCRP) levels, an essential indicator of systemic inflammation, by 43.4%, whereas the placebo group registered a 3.5% reduction.The overall safety profile of tirzepatide during the SUMMIT trial was consistent with previous study findings. The majority of adverse events were mainly gastrointestinal and deemed mild to moderate in severity. The most commonly reported adverse events among tirzepatide users, compared to placebo, were diarrhea, nausea, and constipation. Discontinuation due to adverse events affected 23 tirzepatide participants and five placebo participants.The material has been provided by InstaForex Company – www.instaforex.com
- Genmab : Epcoritamab Combo Shows High Response Rates In 1b/2 Trial For R/R Follicular Lymphoma - December 8, 2024
- Saudi Arabia’s GDP Growth Stagnates at 2.80% in Third Quarter Year-over-Year, Matching Previous Year - December 8, 2024
- Nektar’s NKTR-255 After CD19 CAR-T Therapy Enhances Complete Response In R/R Large B-Cell Lymphoma - December 8, 2024
